{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-23-000157","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2023-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.206131+00:00","generated_at":"2026-06-07T20:21:21.716829+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"John Quisel appointed to Gossamer Bio Board; brings PAH expertise from Acceleron/Merck","bullets":["Appointed Class III director, term expiring at 2024 annual meeting; joins Audit Committee.","Received option to purchase 230,000 shares vesting monthly over three years, plus $40,000 board retainer and $7,500 audit retainer annually.","Currently President & CEO of Disc Medicine; previously at Acceleron Pharma leading re-acquisition of sotatercept rights for PAH from Bristol-Myers Squibb.","Led initiative that culminated in Merck's $11B acquisition of Acceleron in 2021, highlighting deep PAH corporate development experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-23-000157","json":"https://secwatch.observer/filing/0001728117-23-000157.json","markdown":"https://secwatch.observer/filing/0001728117-23-000157.md","text":"https://secwatch.observer/filing/0001728117-23-000157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000157/0001728117-23-000157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000157/goss-20231128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:21:21.716829+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d538a00a7","claim":"John Quisel was appointed as Class III Director at Gossamer Bio, Inc..","evidence_excerpt":"the Board appointed John Quisel, J.D., Ph.D. to serve as a Class III director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000157/0001728117-23-000157-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}